SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending following its announcement of a record date for a digital token initiative, drawing significant community discussion around its venture into crypto. This attention is amplified by escalating geopolitical rhetoric, including commentary on Greenland and new tariff threats, which is heavily influencing market sentiment and broader economic concerns. The stock continues to be a focal point for politically charged narratives, with both enthusiastic supporters and market participants expressing strong, polarized views.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to regulatory clarity for ANKTIVA's resubmission for papillary bladder cancer, requiring no new clinical trials, coupled with expanding international approvals. The community is actively discussing the potential for a significant short squeeze, driven by high short interest and exceptional volume, as many investors embrace the long-term "cancer cure" narrative. This optimism persists even as the broader market faces headwinds, highlighting IBRX's standout performance and promising pipeline.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community closely follows its ongoing interactions with the FDA regarding the Biologics License Application for its Duchenne muscular dystrophy treatment, deramiocel, and the forthcoming submission of the full HOPE-3 clinical study report. Sentiment is divided, with many expressing strong bullishness and anticipating significant upside potential, while others voice concerns over perceived delays and discuss potential market manipulation, as analysts reiterate positive ratings for the company.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant non-exclusive licensing deal with Pfizer for its Matrix-M adjuvant, a move widely seen as powerful validation for the platform technology beyond its initial COVID application. The community is actively debating whether this partnership signals NVAX's evolution into a royalty-generating company and if high short interest will trigger a substantial upward move, despite some expressing frustration over the immediate market reaction amidst a broader downturn.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group Holding Ltd. is currently trending due to news of a strategic acquisition and a recent public offering that sparked extreme volatility. The community is sharply divided between anticipating massive upside driven by its low float and projected profitability, and expressing caution over its significant price swings. Traders are actively debating if this presents a compelling buying opportunity or a cautionary tale, drawing parallels to other high-momentum low-float stocks.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to highly positive Phase 1 clinical trial results for its drug, soquelitinib, in treating moderate to severe atopic dermatitis. This early data, especially in patients resistant to other treatments, is fueling community excitement about its potential as a significant new option in a large market, with discussions also revolving around the possibility of strategic partnerships or a buyout, alongside concerns about the drug's early development stage.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending following its acquisition of Texas Critical Data Centers and a new partnership to co-develop a large-scale AI data center campus in West Texas. The community is actively discussing an anticipated hyperscaler tenant announcement, which many believe could significantly boost the stock. Despite some lingering concerns over past allegations, investors are keenly focused on the company's strategic advancements in the high-demand AI infrastructure sector.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending as the community eagerly discusses its strategic expansion plans, including a new rare earth facility in France backed by government support, alongside advancements at its Stillwater magnet plant. These developments are viewed within the broader context of increasing geopolitical tensions and a global push for rare earth independence from traditional suppliers, though some express frustration over consistent price resistance and perceived manipulation compared to sector peers.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing an unprecedented surge driven by escalating AI demand for memory chips, leading to a global supply shortage. This momentum is reinforced by significant capacity expansion initiatives, including a Taiwan fab acquisition and a New York megafab groundbreaking, alongside notable insider buying and analyst upgrades. While many celebrate its "monster" rally and market-leading strength, a segment of the community remains cautious, labeling it an "overextended" "bubble stock" due for a pullback.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is a major talking point as geopolitical tensions escalate over the US's pursuit of Greenland and potential tariffs, prompting a Danish pension fund to divest from US Treasuries citing credit risk concerns. The community remains sharply divided, with some fearing broader international divestment and higher yields while others anticipate eventual rate cuts amid a slowing economy and increased Fed intervention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The financing uses a single-asset SPV, allowing BioAtla to fund a pivotal study without a broader equity raise.</li><li>BioAtla retains majority ownership of Oz-V, keeping 65% control across solid tumor indications after the transaction closes.</li><li>Phase 3 enrollment is expected to begin in early 2026.</li></ul>Shares of BioAtla Inc. (BCAB) slipped nearly 4% in premarket trading on Wednesday after early gains faded, as investors weighed the structure of the company’s $40 million special purpose vehicle (SPV) financing to advance its lead cancer program.<h2 class="st-heading-2">SPV Deal Funds Late-Stage Trial</h2>BioAtla said the SPV transaction with GATC Health Corp. is designed to fund a registrational Phase 3 trial of ozuriftamab vedotin (Oz-V) in patients whose oropharyngeal cancer has progressed after prior treatments.&nbsp;The company will receive an initial $5 million to support general operations and trial expenses, with the remaining $35 million expected to close in the first quarter of 2026 as the study begins.Following completion, BioAtla will retain 65% ownership of Oz-V across all solid tumor indications, while the SPV, backed by Inversagen AI LLC, will hold the remaining 35%.<h2 class="st-heading-2">Investor Focus On Structure</h2>The single-asset SPV approach allows BioAtla to fund a pivotal trial without a broader equity raise, but the structure appeared to draw a cautious response from investors after the initial premarket rally. Under the arrangement, the SPV will share in future development and commercialization economics for Oz-V.<h2 class="st-heading-2">Phase 3 Path&nbsp;</h2>BioAtla will lead execution of the Phase 3 study, with patient enrollment expected to begin in early 2026.&nbsp;The company said the trial is intended to support a potential accelerated approval pathway in the U.S. Oz-V has received Fast Track designation from the FDA for recurrent or metastatic squamous cell carcinoma of the head and neck.<h2 class="st-heading-2">BioAtla Retains Lead Role On Oz-V</h2>The company said the financing provides a near-term path to advance Oz-V while preserving majority ownership, and noted ongoing discussions around expanding the drug’s use into other HPV-positive solid tumors, including cervical cancer.&nbsp;BioAtla and GATC Health also expect to collaborate with Inversagen AI on additional research tied to senescence and longevity technologies, with BioAtla retaining rights for cancer applications.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for BioAtla was ‘bearish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:973/141;" src="https://news.stocktwits-cdn.com/bcab_ss_png_1ab7393b71.webp" alt="bcab ss.png" width="973" height="141"><figcaption>BCAB sentiment and message volume as of December 31| Source: Stocktwits</figcaption></figure>One user said the market had yet to fully price in the $40 million upfront component of the deal.<stembedurl>https://stocktwits.com/BiotechValues/message/640486061</stembedurl>Another user said the deal fell short of a true global license agreement, pointing instead to the SPV structure and its terms.<stembedurl>https://stocktwits.com/SDBiotechInvestor/message/640485518</stembedurl><a href="https://stocktwits.com/symbol/BCAB">BioAtla’s stock</a> has risen 21% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioAtla logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial

The company disclosed the terms and timeline of an SPV arrangement tied to its Oz-V development program.

Equity

Big short fame Michael Burry-run Scion Asset Management’s September quarter 13F <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1649339/000090514824003106/xslForm13F_X02/informationtable.xml">report</a> filed late Thursday showed increased exposure to its China stock holdings Alibaba Group Holding Ltd. (<a class="mention" data-mention="$BABA" data-symbol-id="BABA" href="https://stocktwits.com/symbol/BABA" target="_blank">$BABA</a>), Baidu, Inc. (<a class="mention" data-mention="$BIDU" data-symbol-id="BIDU" href="https://stocktwits.com/symbol/BIDU" target="_blank">$BIDU</a>) and JD.com. Inc. (<a class="mention" data-mention="$JD" data-symbol-id="JD" href="https://stocktwits.com/symbol/JD" target="_blank">$JD</a>). The hedge-fund manager, however, covered much of his positions in these stocks with put options.&nbsp;Burry is known for accurately predicting the 2007 subprime mortgage crisis that later morphed into the global financial crisis.At the end of the third quarter, Scion held 200,000 Alibaba ADRs valued at $21.22 million, up from 155,000 ADRs worth $11.16 million at the end of the second quarter.He hedged his Alibaba bet by buying put options on 168,900 ADRs. This strategy insulates him against any potential drop in Alibaba shares.&nbsp;Alibaba shares have rebounded nicely this year amid China’s concerted efforts to stimulate domestic growth. The e-commerce giant is scheduled to report its second-quarter results before the market opens on Friday.Burry’s firm increased its Baidu holding from 75,000 ADRs, valued at $6.49 million, to 125,000 ADRs worth $13.16 million. It also bought put options on 83,000 Baidu ADRs.The firm loaded up ADRs of Alibaba’s peer JD, increasing its stake in the company from 250,000 ADRs to 500,000 ADRs. The value of JD,com holdings swelled from $6.46 million to $20 million. Bury also bought puts on JD.com for 500,000 in underlying shares.On the other hand, Burry halved RealReal, Inc. (<a class="mention" data-mention="$REAL" data-symbol-id="REAL" href="https://stocktwits.com/symbol/REAL" target="_blank">$REAL</a>) holdings from 1 million shares to 500,00 shares. It also significantly cut its stake in&nbsp;American Coastal Insurance Corporation (<a class="mention" data-mention="$ACIC" data-symbol-id="ACIC" href="https://stocktwits.com/symbol/ACIC" target="_blank">$ACIC</a>) from 251,892 to 100,000.Scion fully cashed out of oncology-focused biotech BioAtla, Inc. (<a class="mention" data-mention="$BCAB" data-symbol-id="BCAB" href="https://stocktwits.com/symbol/BCAB" target="_blank">$BCAB</a>) and office real estate investment trust Hudson Pacific Properties, Inc. (<a class="mention" data-mention="$HPP" data-symbol-id="HPP" href="https://stocktwits.com/symbol/HPP" target="_blank">$HPP</a>).On Stocktwits, sentiment towards Burry’s China holdings is muted.&nbsp;Sentiment toward Alibaba was 'neutral' on Stocktwits platform, although improving from a 'bearish' stance a day ago.<figure class="image"><a href="https://stocktwits.com/symbol/BABA"><img style="aspect-ratio:632/133;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/baba_bury_sentiment_76d1568b0e.png" alt="baba-bury-sentiment.png" width="632" height="133"></a><figcaption>BABA sentiment and message volume November 15, 2024 premarket as of 4:06 am ET | Source:&nbsp;Stocktwits</figcaption></figure>&nbsp;JD.com elicited 'bearish sentiment' (36/100) from the retail, although message activity remained 'extremely high,' possibly due to the earnings report released Thursday.<figure class="image"><a href="https://stocktwits.com/symbol/JD"><img style="aspect-ratio:630/135;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/jd_sentiment_cffa43fe76.png" alt="jd-sentiment.png" width="630" height="135"></a><figcaption>JD sentiment and message volume November 15, 2024 premarket as of 4:06 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Baidu did not fare any better, with the retail mood 'bearish' (45/100) on Stocktwits, although message volume, a proxy for activity, was 'high.'<figure class="image"><a href="https://stocktwits.com/symbol/BIDU"><img style="aspect-ratio:632/140;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/bidu_sentiment_fb301f5932.png" alt="bidu-sentiment.png" width="632" height="140"></a><figcaption>BIDU sentiment and message volume November 15, 2024 premarket as of 4:06 am ET | Source:&nbsp;Stocktwits</figcaption></figure>As of 4:06 am ET, Alibaba shares eased 0.63% to $90.01, while JD.com climbed 1.83% to $33.96 and Baidu gained 1.18% to $85.05.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/warren-buffett-s-berkshire-initiates-positions-in-domino-s-pizza-pool-corp-does-retail-share-the-sentiment/cJ4F7DqRfp">Warren Buffett’s Berkshire Initiates Positions In Domino’s Pizza, Pool Corp: Does Retail Share The Sentiment?</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Chinese stocks are seeing green shoots of recovery amid stimulus measures to reinvigorate growth.

Michael Burry Cautiously Ups Alibaba, JD.com, Baidu Bets With Offsetting Hedges: Retail Doesn’t Share Big Short Investor’s Optimism

Burry is known for accurately predicting the 2007 subprime mortgage crisis that later morphed into the global financial crisis.

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Current Price	$0.3381
Prev Close	$0.3222
Open	$0.34
Dividend Yield	0.00%
50-Day Moving Average	$0.7099
Beta	1.84
Avg. Volume	1.54M
PE Ratio	-0.28

52-Week High	$1.43
52-Week Low	$0.24
Market Capitalization	$20.63M
EPS (Annual)	-$1.44
Price to Book	-0.61
Revenue Per Employee	$144,736.84
Enterprise Value/EBITDA	N/A

BCAB
BioAtla Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCAB News

BCABBioAtla Inc